TheraRadar
← Back
Data updated: Jul 17, 2026

JIANGSU HENGRUI MED

Pharma
OncologyMetabolicGastroenterology Execution: Fair

JIANGSU HENGRUI MED is a pharmaceutical company focused on Oncology, Metabolic, Gastroenterology.

-
Since
0
Drugs
-
Trials
0
New Drugs (2yr)

JIANGSU HENGRUI MED at a Glance

  • Fast trial execution (12 months median completion)

JIANGSU HENGRUI MED's Key Drugs

JIANGSU HENGRUI MED's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

JIANGSU HENGRUI MED's Recent FDA Approvals

New NDA/BLA approvals for JIANGSU HENGRUI MED over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

JIANGSU HENGRUI MED's Therapeutic Areas

JIANGSU HENGRUI MED's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 73%
0 drugs Phase 3: 41 Phase 2: 43 Phase 1: 101
Metabolic 13%
0 drugs Phase 3: 5 Phase 2: 9 Phase 1: 24
Gastroenterology 7%
0 drugs Phase 3: 5 Phase 2: 3 Phase 1: 6
Immunology 4%
0 drugs Phase 3: 1 Phase 2: 4 Phase 1: 7
Cardiovascular 4%
0 drugs Phase 3: 3 Phase 1: 6

JIANGSU HENGRUI MED's Top Competitors

JIANGSU HENGRUI MED's closest competitors by therapeutic-area and drug-target overlap include Takeda, Johnson & Johnson, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Takeda big-pharma
Immunology, Metabolic, Gastroenterology, Oncology, Cardiovascular
Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Immunology, Cardiovascular
Amgen biotech
Oncology, Immunology, Metabolic, Cardiovascular, Gastroenterology
AstraZeneca big-pharma
Oncology, Metabolic, Cardiovascular, Immunology

JIANGSU HENGRUI MED Pipeline Snapshot

JIANGSU HENGRUI MED has 258 active clinical programs from ClinicalTrials.gov — 55 Phase 3, 59 Phase 2 and 144 Phase 1.

55
Phase 3
59
Phase 2
144
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 40/81 completed
  • • Speed: 12 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges